A Comparison of Mometasone to Advair in Patients With Milder Persistent Asthma

Phase 4TerminatedNCT00461812

Johns Hopkins University33 enrolled

Overview

The research hypothesis for the proposed study asks the question, can Asmanex® demonstrate comparable anti-inflammatory therapeutic efficacy to the combination product, Advair® in control of mild persistent asthma? The purpose is to demonstrate that the anti-inflammatory protection afforded by monotherapy with an inhaled steroid (Asmanex®) is comparable to combination therapy with Advair® 100/50, when measured by this standard methodology (methacholine bronchoprovocation) in subjects with mild persistent asthma.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Asthma

Interventions

MometasoneDRUG

AdvairDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * subjects 18 to 65 years of age * a \>2 year history of asthma * FEV1 \> 80% for subjects currently using Advair®. Exclusion Criteria: * severe asthma * current smokers * pregnant or breast-feeding women * other chronic significant illnesses

Locations (1)

Johns Hopkins Asthma and Allergy Center

Baltimore, Maryland, United States

Outcomes

Primary Outcomes

Efficacy as Assessed my Pulmonary Function Tests

Time frame: change from baseline to study completion

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.